490 ARSENAL WAY, WATERTOWN, MA
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
C4 Therapeutics Advances Cemsidomide, Targets Novel Pathways
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Investor Presentation
C4 Therapeutics Enters Underwriting Agreement for 21.9M Share Offering
C4 Therapeutics and Pfizer Collaborate on Multiple Myeloma Treatment Trial
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus